When the Lung Master Protocol clinical trial (Lung-MAP or S1400) (1) was launched in June 2014, the goal of this first-of-its kind trial was simple: find effective treatments for seriously ill patients suffering from a specific type of lung cancer.
How the Lung-MAP Clinical Trial is Responding to Rapidly Changing Science
Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
Co-principal investigator, Lung-MAP trial
Chief of Medical Oncology, associate director for translational research, Yale Cancer Center
Chief of Medical Oncology, associate director for translational research, Yale Cancer Center
Co-principal investigator, Lung-MAP trial; Director, Thoracic Oncology Program, University of California, Davis
Co-principal investigator, member of oversight and drug selection committees, Lung-MAP trial; professor, Department of Thoracic/Head and Neck Medical Oncology, MD Anderson Cancer Center
Table of Contents
YOU MAY BE INTERESTED IN
More than half of deaths that are not attributed to disease progression or recurrence after CAR T-cell therapy are caused by infections—an unprecedented finding that experts say marks a shift from a conventional focus on mitigating treatment-specific adverse events to including prevention and management of infections.
Christy Erickson was seven years old when her mom lost a three-year battle with breast cancer.
Two decades after uncovering the role of EGFR mutations in lung cancer, scientists are still grappling with lingering research questions.
Lei Zheng was named executive director of the Mays Cancer Center, home to UT Health San Antonio MD Anderson Cancer Center, and vice president for oncology for the University of Texas Health Science Center at San Antonio.
Mark Burkard was named director of University of Iowa Health Care Holden Comprehensive Cancer Center.
